Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% ...

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug ...

Merck said it is embarking on a multi-year cost-savings plan, which includes cuts to its workforce and real-estate footprint, ...

Investors are worried how the company will handle the 2028 expiration of the U.S. patents protecting Keytruda, Merck’s ...

If you're looking for high-yield stocks in the healthcare sector, it's hard to beat this trio of industry giants offering ...

Science does not support aluminum as a culprit of autism. Yet RFK Jr. and his associates continue to find ways to support the ...

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...

Plunging sales of Merck’s blockbuster HPV vaccine in China have caused a sharp fall in the US pharma group’s earnings. In ...

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

Merck (NYSE:MRK) on Tuesday reported second-quarter earnings and revenue that beat and missed analyst expectations, respectively, while narrowing its outlook for the year.

Merck (MRK) is cutting $3 billion from its annual expenses as it prepares for generic competition to its blockbuster cancer drug, Keytruda.

On a per-share basis, the Rahway, New Jersey-based company said it had profit of $1.76. Earnings, adjusted for one-time gains and costs, were $2.13 per share. The results topped Wall Street ...